PMID- 32175895
OWN - NLM
STAT- MEDLINE
DCOM- 20200918
LR  - 20200918
IS  - 2589-1294 (Electronic)
IS  - 1017-995X (Print)
IS  - 1017-995X (Linking)
VI  - 54
IP  - 1
DP  - 2020 Jan
TI  - Clinicopathological value of ErbB2 gene and protein expression in osteochondroma.
PG  - 34-41
LID - 10.5152/j.aott.2020.01.484 [doi]
AB  - OBJECTIVE: The aim of this study was to investigate ErbB2 expression in 
      osteochondroma and its relationship with clinicopathologic features of 
      osteochondroma, so as to identify a new biomarker for the malignant 
      transformation potential of osteochondroma. METHODS: Immunohistochemistry (IHC) 
      and fluorescence in situ hybridization (FISH) were used to investigate the 
      expression status of ErbB2 protein and gene in 30 osteochondroma tissues and 20 
      non-neoplastic bone tissues. The association of ErbB2 gene and protein expression 
      with clinicopathological parameters of osteochondroma was analyzed by using the 
      chi2 test and Fishers exact test. RESULTS: ErbB2 protein was found to be 
      over-expressed in 4 of 30 (13.3%) osteochondromas and 1 of 20 (5%) non-neoplastic 
      bone samples, which were not statistically significant (p=0.336). However, 13 of 
      the 30 (43.3%) osteochondromas showed ErbB2 gene amplification, which was failed 
      to be observed in any of the non-neoplastic bone tissue. ErbB2 gene amplification 
      in osteochondroma was significantly higher compared with that in non-neoplastic 
      bone tissue (p=0.001). In addition, the ErbB2 gene amplification was closely 
      associated with clinical pathological parameters of osteochondroma, including 
      high expression of cellularity (p=0.001), presence of binucleated cells 
      (p=0.001), nuclear pleomorphism (p=0.003), calcification (p=0.002), nodularity 
      (p=0.002), necrosis (p=0.009) and cartilage thickness (p=0.026). The association 
      of the gene amplification with other clinicopathological parameters of 
      osteochondroma, including permeation of trabecular bone, cystic/mucoid changes, 
      mitosis, radiographic appearance, cap volume and subtype of osteochondroma was 
      not observed. The over-expression of ErbB2 protein was not found to be associated 
      with the above stated clinical pathological parameters of osteochondroma. 
      CONCLUSION: ErbB2 gene amplification was associated with adverse 
      clinicopathological status of osteochondroma and could serve as an index for 
      malignant conversion of osteochondroma. Further research is required to verify 
      the predictive values of ErbB2 for osteochondroma. LEVEL OF EVIDENCE: Level IV, 
      Diagnostic Study.
FAU - Huang, Zhen
AU  - Huang Z
AD  - Department of Orthopedics, First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, China.
FAU - Wang, Sheng-Lin
AU  - Wang SL
AD  - Department of Orthopedics, First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, China.
FAU - Huang, Qing-Shan
AU  - Huang QS
AD  - Department of Orthopedics, First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, China.
FAU - Li, Xiao-Dong
AU  - Li XD
AD  - Department of Orthopedics, First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, China.
FAU - Chen, Hui
AU  - Chen H
AD  - Fujian Provincial Institute of Orthopedic, First Affiliated Hospital of Fujian 
      Medical University, Fuzhou, China.
FAU - Lin, Jian-Hua
AU  - Lin JH
AD  - Department of Orthopedics, First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, China;Fujian Provincial Institute of Orthopedic, First 
      Affiliated Hospital of Fujian Medical University, Fuzhou, China.
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Acta Orthop Traumatol Turc
JT  - Acta orthopaedica et traumatologica turcica
JID - 9424806
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - *Bone Neoplasms/genetics/pathology
MH  - Cell Transformation, Neoplastic/genetics
MH  - China/epidemiology
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - *Osteochondroma/genetics/pathology
MH  - Receptor, ErbB-2/*genetics
PMC - PMC7243691
COIS- Conflict of Interest: The authors have no conflicts of interest to declare.
EDAT- 2020/03/17 06:00
MHDA- 2020/09/20 06:00
PMCR- 2020/01/01
CRDT- 2020/03/17 06:00
PHST- 2020/03/17 06:00 [entrez]
PHST- 2020/03/17 06:00 [pubmed]
PHST- 2020/09/20 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - aott-53-1-34 [pii]
AID - 10.5152/j.aott.2020.01.484 [doi]
PST - ppublish
SO  - Acta Orthop Traumatol Turc. 2020 Jan;54(1):34-41. doi: 
      10.5152/j.aott.2020.01.484.